{
    "relation": [
        [
            "",
            "STARTED",
            "COMPLETED",
            "NOT COMPLETED"
        ],
        [
            "Healthy Subjects",
            "0",
            "0",
            "0"
        ],
        [
            "Mild Renal Impairment",
            "0",
            "0",
            "0"
        ],
        [
            "Moderate Renal Impairment",
            "0",
            "0",
            "0"
        ],
        [
            "Severe Renal Impairment",
            "6",
            "6",
            "0"
        ],
        [
            "ESRD: Single Dose",
            "0",
            "0",
            "0"
        ]
    ],
    "pageTitle": "Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00717067?sect=Xf0156&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 5,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042990217.27/warc/CC-MAIN-20150728002310-00282-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 875637055,
    "recordOffset": 875618681,
    "tableOrientation": "VERTICAL",
    "textBeforeTable": "Period 1: \u00a0 Part 1a: Normal/Mild/Moderate Group Participant Flow for 3 periods (I) Maraviroc single dose one hour following completion of morning hemodialysis, followed at least 1 week later by (II) Maraviroc single dose three hours prior to start of hemodialysis. ESRD: Single Dose Maraviroc 300 mg single dose. Severe Renal Impairment Maraviroc 150 mg every 48 hours co-administered with saquinavir 1,000 mg/ritonavir 100 mg twice a day (BID) for 7 days. Moderate Renal Impairment Maraviroc 150 mg once a day (QD) co-administered with saquinavir 1,000 mg/ritonavir 100 mg twice a day (BID) for 7 days. Mild Renal Impairment (I) Maraviroc single 300 mg dose, followed 4 days later by (II) Maraviroc 150 mg twice a day (BID) co-administered with saquinavir 1,000 mg/ritonavir 100 mg twice a day (BID) for 6 days, and a single dose of both agents on Day 7. Healthy Subjects Description \u00a0 Reporting Groups Subjects were enrolled into treatment groups (healthy subjects, mild, moderate,",
    "textAfterTable": "Adverse Event \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 1 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 0 \u00a0 Period 2: \u00a0 Part 1b: Severe Renal Impairment \u00a0 \u00a0 Healthy Subjects \u00a0 \u00a0 Mild Renal Impairment \u00a0 \u00a0 Moderate Renal Impairment \u00a0 \u00a0 Severe Renal Impairment \u00a0 \u00a0 ESRD: Single Dose \u00a0 STARTED \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 \u00a0 6 \u00a0 \u00a0 0 \u00a0 COMPLETED \u00a0 \u00a0 0 \u00a0 \u00a0",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}